Radiomic Features Predicts Early Response to CDK4/6 Inhibitors in Patients With HR+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
NPJ Breast Cancer 2023 Aug 11;9(1)67, M Khorrami, VS Viswanathan, P Reddy, N Braman, S Kunte, A Gupta, J Abraham, AJ Montero, A MadabhushiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.